The United States continues to face a public health crisis of opioid-related harm, the effects of which could be dramatically reduced through increased access to opioid agonist therapy with the medications methadone and buprenorphine. Despite overwhelming evidence of their efficacy, unduly restrictive federal, state, and local regulation significantly impedes access to these life-saving medications. This commentary outlines immediate, concrete steps that federal, state, and local governments can take to change law from barrier to facilitator of evidence-based treatment for opioid use disorder.
Recent Abstracts
More Data Better Health – Brazilian People’s Perceptions of Risk Factors for Cancer
Relatório de Atividades 2025 – Brasil
Mais Dados Mais Saúde – Percepções da população brasileira sobre fatores de risco…
What Primary Care Records Reveal About Cancer Signs and Symptoms
O que os prontuários da atenção primária revelam sobre sinais e sintomas de…
CRVS Performance Measurement and Monitoring Resource Kit
Model Kentucky Ordinance Establishing a County Opioid Abatement Advisory Council
The invisible pain: Gaps in Brazil’s public health system data on Menstrual and…
Exploring the Interface Between Birth Registration and Citizenship Determination: A Scoping Study in…
A dor invisível: lacunas nos dados do SUS sobre dor menstrual e pélvica